- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01941121
CCTG 593: Testing and Linkage to Care
CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group
This is a CCTG sponsored project to determine if those recently screened for HIV would accept assistance to be linked into appropriate health services. After receiving their HIV results, high-risk individuals who test negative will have an option to be linked into a study that offers them Pre-exposure Prophylaxis (PrEP), and individuals who test positive will have an option to be linked into care.
If they accept, tested individuals will be in contact with an ALERT specialist that will help facilitate their linkage. The study's primary analysis will analyze how many HIV screened individuals accept the ALERT specialist assistance.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Design: CCTG 593 is a project to evaluate the uptake and effectiveness of an ALERT specialist serving to
- link newly diagnosed, HIV infected persons from HIV testing sites to HIV specialist providers, and
- link confirmed HIV antibody negative persons with continued high risk behaviors to PrEP centers
Duration: Each subject who agrees to linkage will receive ALERT follow-up until successful linkage or 60 days following enrollment for linkage to care or 90 days following enrollment for linkage to PrEP, whichever comes first. The duration of the 593 project will be for 3.5 years or until all subjects have been enrolled and successfully linked, or 60 days pass for linkage to care or 90 days for linkage to PrEP.
Sample Size: Up to 600 subjects will be tested and offered linkage across all CCTG sites: LA County-USC Medical Center, Harbor-UCLA/City of Long Beach Department of Health and Human Services, UCSD/San Diego Health and Human Services Agency.
Study Population: Eligible subjects will include any persons 18 years of age or older who have been tested for HIV at one of the CCTG testing sites (LA County + USC, Long Beach Department of Health and Human Services, and San Diego Health and Human Services Agency).
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
California
-
Long Beach, California, Forenede Stater, 90815
- City of Long Beach Department of Health and Human Services
-
Los Angeles, California, Forenede Stater, 90033
- University of Southern California
-
San Diego, California, Forenede Stater, 92103
- University of California, San Diego
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Has had an HIV test result form the CCTG Consortium testing site as either positive or negative
- Ability to provide informed consent
- English or Spanish Speaking
Exclusion Criteria:
- Severe active substance abuse or mental illness that the investigator feels will interfere with the ability to provide informed consent
- Acute medical illness that requires transfer to a non CCTG hospital
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Linkage to PrEP or Care
Subjects screened for HIV at any CCTG consortium site will be offered Linkage to PrEP or Care, depending on HIV status.
After results are received, HIV testers will obtain verbal consent from the subject to connect with the ALERT Specialist, or otherwise offer the subject the ALERT Specialist contact information.
When contacted, the ALERT Specialist will coordinate with the subject the scheduling of the PrEP or Care visit, and remain in contact to ensure linkage.
|
Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of subjects linked to Care or PrEP
Tidsramme: Up to 60 days for positives and up to 90 days for negatives from date of HIV screening test
|
The primary outcome will measure the proportion of subjects linked a) to HIV care within 60 days of testing HIV-positive or b) to PrEP within 90 days of testing HIV-negative
|
Up to 60 days for positives and up to 90 days for negatives from date of HIV screening test
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acceptance of the linkage program
Tidsramme: 60 days from date of HIV screening test
|
Secondary outcomes will measure the acceptance of the linkage program, which is defined as those individuals who, after testing either positive or HIV antibody negative, will agree to be contacted by the ALERT specialist.
|
60 days from date of HIV screening test
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: Kathleen Jacobson, MD, University of Southern California
- Studiestol: Michael Menchine, MD, MPH, University of Southern California
- Ledende efterforsker: Jill Blumenthal, MD, UC San Diego AntiViral Research Center (AVRC)
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CCTG 593
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV positiv
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)AfsluttetHIV positivForenede Stater
-
Therapeutic ConceptsJanssen Scientific Affairs, LLCUkendt
-
Universidad Autónoma del Estado de HidalgoNational Council of Science and Technology, MexicoAfsluttet
-
Bayside HealthMerck Sharp & Dohme LLCUkendt
-
Holdsworth House Medical PracticeAfsluttet
-
QIAGEN Gaithersburg, IncAfsluttet
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California HIV/AIDS Research Program og andre samarbejdspartnereAfsluttetPatienttilslutning | HIV positivForenede Stater
-
Elizabeth Glaser Pediatric AIDS FoundationHarvard School of Public Health (HSPH); Centre for Infectious Disease Research... og andre samarbejdspartnereAfsluttetHIV-infektioner | Gravid kvinde | HIV positivSydafrika, Zambia
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy...AfsluttetHIV positivIndonesien, Ukraine, Vietnam
-
Abbott Diagnostics DivisionAfsluttetHIV positiv | Sunde donorerForenede Stater
Kliniske forsøg med Linkage to PrEP or Care
-
Hebei Senlang Biotechnology Inc., Ltd.The Second Hospital of Hebei Medical UniversityRekrutteringAkut lymfoblastisk leukæmi i barndommenKina
-
Population CouncilUniversity of ZimbabweAfsluttetHIV-infektioner | SvangerskabsforebyggelseZimbabwe
-
UNC Lineberger Comprehensive Cancer CenterIkke længere tilgængelig
-
National Cancer Institute (NCI)AfsluttetLymfom, B-celle | Kronisk lymfatisk leukæmi | Lymfom, Non-hodgkins | B-celle kronisk lymfatisk leukæmiForenede Stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringPlatin-resistent ovariekarcinomForenede Stater
-
National Cancer Institute (NCI)RekrutteringLymfom, Non-Hodgkin | Akut lymfatisk leukæmi | Akut lymfatisk leukæmi | Akut lymfoid leukæmi | B-celle leukæmi | Leukæmi, lymfocytisk, B-celle | B-celle lymfom | Bold | B-NHL | B-Non Hodgkin lymfom | B-forløber ALLEForenede Stater
-
Population CouncilAktiv, ikke rekrutterende
-
Marcela V. Maus, M.D.,Ph.D.RekrutteringMyelomatose | Refraktær Myelom | Myelom i tilbagefaldForenede Stater
-
Henan Cancer HospitalThe Pregene (ShenZhen) Biotechnology Company, Ltd.Ukendt
-
Henan Cancer HospitalThe Pregene (ShenZhen) Biotechnology Company, Ltd.UkendtB-celle akut lymfatisk leukæmiKina